Breast Cancer
Conditions
Keywords
Metformin, Pharmacokinetics, Organic cation transporter, Multidrug and toxin extrusion, Pharmacogenetics, positron emission tomography
Brief summary
The general purpose of the trial is to investigate whether metformin is taken up into the breast tumor. Studies in the last few years have shown an effect of metformin on cell proliferation on breast cancer. It is though unclear whether the effect on tumor is direct, indirect or a combination of the two. The investigators plan to: * investigate if metformin is taken up in breast cancer using our novel 11C-metformin tracer and positron emission tomography (PET) * investigate whether the uptake is correlated to the amounts of organic cation transporters (OCT1-3, MATE 1 &2 and PMAT) using quantitive polymerase chain reaction (qPCR).
Interventions
RADIATION11C-metformin
400MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Position Emission Tomography.
Sponsors
Aarhus University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
11C-metformin uptake in breast cancer. Single center, single dose, open-label.
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* over 50 years * C. mammae * Tumor size: \> 10 mm in diameter * Unilateral cancer * WHO performance status 0-1
Exclusion criteria
* Severe heart- or kidney failure * Pregnant or breast feeding * If the patient is found not eligible for participation in the study på principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Metformin uptake in breast cancer | 12 months |
Countries
Denmark
Outcome results
None listed